Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis

International Journal of Cancer

Volumn 137, Issue 8, 2015, Pages 2029-2039

  Yang, Xiaoqian ^a,b   Shen, Jacson ^a   Gao, Yan ^a   Feng, Yong ^a   Guan, Yichun ^a,b   Zhang, Zhan ^b   Mankin, Henry ^a   Hornicek, Francis J ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

apoptosis; NSC23925; ovarian cancer; paclitaxel resistance; Pgp

Indexed keywords

GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; [2 (4 METHOXYPHENYL) 4 QUINOLINYL](2 PIPERPIPERIDINYL); (2-(4-METHOXYPHENYL)-4-QUINOLINYL)(2-PIPERIDINYL)METHANOL; ANTINEOPLASTIC AGENT; PIPERIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; CANCER MODEL; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT CHANGE; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PIPERIDINES; QUINOLINES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939588813     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29574     Document Type: Article

References (48)

1. Siegel R, Ma J, Zou Z, et al., Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Herzog TJ,. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004; 10: 7439-49.
3. Coleman RL, Monk BJ, Sood AK, et al., Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013; 10: 211-24.
4. Bookman MA, Gilks CB, Kohn EC, et al., Better therapeutic trials in ovarian cancer. J Natl Cancer Inst 2014; 106: dju029.
5. Lortholary A, Largillier R, Weber B, et al., Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from groupe d'investigateurs nationaux pour l'etude des cancers ovariens (GINECO). Ann Oncol 2012; 23: 346-52.
6. Banerjee S, Kaye SB,. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013; 19: 961-8.
7. Baird RD, Kaye SB,. Drug resistance reversal-are we getting closer? Eur J Cancer 2003; 39: 2450-61.
8. Murray S, Briasoulis E, Linardou H, et al., Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 2012; 38: 890-903.
9. Le XF, Bast RC, Jr., Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 2011; 12: 260-9.
10. Zaffaroni N, Pennati M, Colella G, et al., Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59: 1406-12.
11. Simonin K, Brotin E, Dufort S, et al., Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol Cancer Ther 2009; 8: 3162-70.
12. Zeimet AG, Reimer D, Sopper S, et al., Ovarian cancer stem cells. Neoplasma 2012; 59: 747-55.
13. Nuti SV, Mor G, Li P, et al., TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis. Oncotarget 2014; 5: 7260-71.
14. Cocker HA, Tiffin N, Pritchard-Jones K, et al., In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 2001; 7: 3193-8.
15. Zatelli MC, Luchin A, Tagliati F, et al., Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 2007; 14: 1029-38.
16. Sargent JM, Williamson CJ, Yardley C, et al., Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, k562. Br J Cancer 2001; 84: 959-64.
17. Fahrig R, Steinkamp-Zucht A, Schaefer A,. Prevention of adriamycin-induced mdr1 gene amplification and expression in mouse leukemia cells by simultaneous treatment with the anti-recombinogen bromovinyldeoxyuridine. Anticancer Drug Des 2000; 15: 307-12.
18. Batrakova EV, Kelly DL, Li S, et al., Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic p85. Mol Pharm 2006; 3: 113-23.
19. Sharma AK, Zhang L, Li S, et al., Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J Control Release 2008; 131: 220-7.
20. Tooker P, Yen WC, Ng SC, et al., Bexarotene (lgd1069, targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 2007; 67: 4425-33.
21. Yen WC, Corpuz MR, Prudente RY, et al., A selective retinoid X receptor agonist bexarotene (targretin) prevents and overcomes acquired paclitaxel (taxol) resistance in human non-small cell lung cancer. Clin Cancer Res 2004; 10: 8656-64.
22. Yen WC, Lamph WW,. The selective retinoid X receptor agonist bexarotene (lgd1069, targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther 2005; 4: 824-34.
23. Baekelandt M, Lehne G, Trope CG, et al., Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol 2001; 19: 2983-93.
24. Fracasso PM, Brady MF, Moore DH, et al., Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 2001; 19: 2975-82.
25. Seiden MV, Swenerton KD, Matulonis U, et al., A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002; 86: 302-10.
26. Lhomme C, Joly F, Walker JL, et al., Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008; 26: 2674-82.
27. Greenberg PL, Lee SJ, Advani R, et al., Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (e2995). J Clin Oncol 2004; 22: 1078-86.
28. Kang MH, Figg WD, Ando Y, et al., The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 2001; 7: 1610 -1 7.
29. Toppmeyer D, Seidman AD, Pollak M, et al., Safety and efficacy of the multidrug resistance inhibitor incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 2002; 8: 670-8.
30. Gandhi L, Harding MW, Neubauer M, et al., A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 2007; 109: 924-32.
31. Pusztai L, Wagner P, Ibrahim N, et al., Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005; 104: 682-91.
32. Duan Z, Choy E, Hornicek FJ,. Nsc23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One 2009; 4: e7415.
33. Duan Z, Li X, Huang H, et al., Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (nsc23925) isomers to reverse multidrug resistance in cancer. J Med Chem 2012; 55: 3113-21.
34. Yang X, Yang P, Shen J, et al., Prevention of multidrug resistance (MDR) in osteosarcoma by nsc23925. Br J Cancer 2014; 110: 2896-904.
35. Duan Z, Zhang J, Choy E, et al., Systematic kinome shRNA screening identifies cdk11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clin Cancer Res 2012; 18: 4580-8.
36. Duan Z, Choy E, Jimeno JM, et al., Diverse cross-resistance phenotype to ET-743 and pm00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol 2009; 63: 1121-9.
37. Holleman A, Chung I, Olsen RR, et al., miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011; 30: 4386-98.
38. Teicher BA, Herman TS, Holden SA, et al., Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990; 247: 1457-61.
39. Duan Z, Foster R, Bell DA, et al., Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006; 12: 5055-63.
40. Duan Z, Lamendola DE, Duan Y, et al., Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005; 55: 277-85.
41. Yusuf RZ, Duan Z, Lamendola DE, et al., Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003; 3: 1-19.
42. Kannan N, Nguyen LV, Eaves CJ,. Integrin beta3 links therapy resistance and cancer stem cell properties. Nat Cell Biol 2014; 16: 397-9.
43. Xiong X, Arvizo RR, Saha S, et al., Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget 2014; 5: 6453-65.
44. Shah V, Taratula O, Garbuzenko OB, et al., Targeted nanomedicine for suppression of cd44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 2013; 19: 6193-204.
45. Agarwal R, Kaye SB,. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-16.
46. Szakacs G, Paterson JK, Ludwig JA, et al., Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
47. Fields A, Hochster H, Runowicz C, et al., PSC833: initial clinical results in refractory ovarian cancer patients. Curr Opin Oncol 1998; 10(Suppl1): S21.
48. Tamaki A, Ierano C, Szakacs G, et al., The controversial role of ABC transporters in clinical oncology. Essays Biochem 2011; 50: 209-32.